A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Biomet, Inc. ( Biomet Orthopedics, LLC )
ClinicalTrials.gov Identifier:
First received: June 13, 2008
Last updated: June 17, 2015
Last verified: June 2015
The purpose of this data collection is to determine long term survival rate of ArComXL® highly cross-linked polyethylene

Avascular Necrosis
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Non-controlled, Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement

Resource links provided by NLM:

Further study details as provided by Biomet, Inc.:

Primary Outcome Measures:
  • Incidence of revisions and removals assessed by the use of a yearly survey mail to patient [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Enrollment: 149
Study Start Date: January 2006
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
ArComXL® polyethylene
ArComXL® polyethylene

Detailed Description:

Approximately 500 patients (cases) will be enrolled in this data collection effort and 10-year follow-up will be attempted. Follow-up will be obtained by sending a questionnaire directly to the patients by mail. The follow-up will be annually and only survivorship data will be collected.

This data collection project was developed in order to determine the actual long-term (10-year) survival rate of Biomet's ArCom XL highly cross-linked polyethylene. Data will be collated for uncemented cases only. This will eliminate the possibility of cement or cement debris being a confounding variable.

The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts, and answer potential questions from reimbursement agencies.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients that have already made the decision to undergo Total Hip Replacement and will recieve ArComXL® polyethylene

Inclusion Criteria:

  • Non inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
  • Rheumatoid Arthritis
  • Correction of Functional Deformity
  • Treatment of non-union, femoral neck fractures, trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Revision of previously failed total hip arthroplasty
  • Uncemented applications

Exclusion Criteria:

Absolute contraindications

  • Infection, sepsis and osteomyelitis

Relative contraindications

  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may be spread to the implant site
  • Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy or neuromuscular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00698152

Sponsors and Collaborators
Biomet Orthopedics, LLC
Study Director: Russell Schenck, PhD Clinical Research, Biomet Orthopedics, Inc.
  More Information

Responsible Party: Biomet, Inc. ( Biomet Orthopedics, LLC )
ClinicalTrials.gov Identifier: NCT00698152     History of Changes
Other Study ID Numbers: ORTHO.CR.H012 
Study First Received: June 13, 2008
Last Updated: June 17, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Biomet, Inc.:
Total Hip Arthroplasty
Total Hip Replacement
Hip Arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on May 24, 2016